{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:10:34Z","timestamp":1753891834866,"version":"3.41.2"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Desmoid tumor is a rare disease, which is histologically characterized by local invasion, monoclonality, and fibroblast proliferation; and clinically characterized by a variable and often unpredictable course. The treatment of desmoid tumor is mainly surgical resection, but the recurrence rate is high. In recent years, a variety of treatment methods, including endocrine therapy, surgery, radiotherapy, chemotherapy, non-steroidal anti-inflammatory drugs, targeted drugs, interferon and more, have been used and achieved certain curative effects. In addition, in view of the inertia characteristics of desmoid tumor, observation is also a first-line scheme recommended by multiple guidelines. In the past, the research progress of targeted therapy for desmoid tumor is relatively slow and the curative effect is limited. Thus, targeted therapy is usually used as a remedial treatment after the failure of other conventional treatment methods. However, in recent years, with the rapid progress in the basic research of targeted therapy, some new targeted drugs are increasingly used for the clinical treatment of desmoid tumor and have achieved good results. Herein, we described a patient with aggressive fibromatosis in the abdominal cavity. Following a combined treatment using anlotinib and celecoxib, the patient achieved a partial response with mild toxicity. Simultaneously, the patient\u2019s pain symptoms completely disappeared. This case indicates that the combination of anlotinib and NSAIDs could be an effective treatment for desmoid tumor.<\/jats:p>","DOI":"10.3389\/fonc.2021.830672","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T04:26:36Z","timestamp":1642047996000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Combination of Anlotinib and Celecoxib for the Treatment of Abdominal Desmoid Tumor: A Case Report and Literature Review"],"prefix":"10.3389","volume":"11","author":[{"given":"Jianzheng","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongle","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingli","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuanye","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huifang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caiyun","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beibei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weifeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuiping","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0025","article-title":"Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology","volume":"16","author":"von Mehren","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"B2","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.hoc.2013.07.008","article-title":"Desmoid Tumors: A Comprehensive Review of the Evolving Biology, Unpredictable Behavior, and Myriad of Management Options","volume":"27","author":"Devata","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"key":"B3","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1097\/00000658-199906000-00014","article-title":"The Enigma of Desmoid Tumors","volume":"229","author":"Lewis","year":"1999","journal-title":"Ann Surg"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.20766","article-title":"Molecular Characterization by Array Comparative Genomic Hybridization and DNA Sequencing of 194 Desmoid Tumors","volume":"49","author":"Salas","year":"2010","journal-title":"Genes Chromosomes Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22272","article-title":"Near Universal Detection of Alterations in CTNNB1 and Wnt Pathway Regulators in Desmoid-Type Fibromatosis by Whole-Exome Sequencing and Genomic Analysis","volume":"54","author":"Crago","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33233","article-title":"Desmoid Tumors: To Treat or Not to Treat, That Is the Question","volume":"126","author":"Kasper","year":"2020","journal-title":"Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq341","article-title":"Imatinib for Progressive and Recurrent Aggressive Fibromatosis (Desmoid Tumors): An FNCLCC\/French Sarcoma Group Phase II Trial With a Long-Term Follow-Up","volume":"22","author":"Penel","year":"2011","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.02.001","article-title":"Imatinib Induces Sustained Progression Arrest in RECIST Progressive Desmoid Tumours: Final Results of a Phase II Study of the German Interdisciplinary Sarcoma Group (GISG)","volume":"76","author":"Kasper","year":"2017","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1177","article-title":"Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research Through Collaboration (SARC) Trial","volume":"16","author":"Chugh","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30276-1","article-title":"Pazopanib or Methotrexate-Vinblastine Combination Chemotherapy in Adult Patients With Progressive Desmoid Tumours (DESMOPAZ): A non-Comparative, Randomised, Open-Label, Multicentre, Phase 2 Study","volume":"20","author":"Toulmonde","year":"2019","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805052","article-title":"Sorafenib for Advanced and Refractory Desmoid Tumors","volume":"379","author":"Gounder","year":"2018","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","article-title":"Safety, Pharmacokinetics, and Antitumor Properties of Anlotinib, an Oral Multi-Target Tyrosine Kinase Inhibitor, in Patients With Advanced Refractory Solid Tumors","volume":"9","author":"Sun","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3766","article-title":"Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients With Refractory Metastatic Soft-Tissue Sarcoma","volume":"24","author":"Chi","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-019-02090-2","article-title":"Anlotinib Inhibits Synovial Sarcoma by Targeting GINS1: A Novel Downstream Target Oncogene in Progression of Synovial Sarcoma","volume":"21","author":"Tang","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.478","article-title":"Anlotinib as a Third-Line Therapy in Patients With Refractory Advanced non-Small-Cell Lung Cancer: A Multicentre, Randomised Phase II Trial (Alter0302)","volume":"118","author":"Han","year":"2018","journal-title":"Br J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4632-y","article-title":"Time Trends in the Incidence and Treatment of Extra-Abdominal and Abdominal Aggressive Fibromatosis: A Population-Based Study","volume":"22","author":"van Broekhoven","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s10006-010-0227-8","article-title":"Aggressive Fibromatosis of the Head and Neck: A New Classification Based on a Literature Review Over 40 Years (1968-2008)","volume":"14","author":"Kruse","year":"2010","journal-title":"Oral Maxillofac Surg"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2016.02.012","article-title":"Extra-Abdominal Desmoid Fibromatosis: A Review of Management, Current Guidance and Unanswered Questions","volume":"42","author":"Eastley","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i46.8793","article-title":"Pancreatic Solid Cystic Desmoid Tumor: Case Report and Literature Review","volume":"19","author":"Xu","year":"2013","journal-title":"World J Gastroenterol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1053\/ejso.2001.1169","article-title":"Desmoid Tumours","volume":"27","author":"Shields","year":"2001","journal-title":"Eur J Surg Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21553","article-title":"Estrogen Receptor-Beta Expression in Extraabdominal Fibromatoses: An Analysis of 40 Cases","volume":"106","author":"Deyrup","year":"2006","journal-title":"Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2007.06.006","article-title":"Extra-Abdominal Primary Fibromatosis: Aggressive Management Could be Avoided in a Subgroup of Patients","volume":"34","author":"Bonvalot","year":"2008","journal-title":"Eur J Surg Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-013-0059-0","article-title":"A Prospective Multicenter Phase II Study of Sunitinib in Patients With Advanced Aggressive Fibromatosis","volume":"32","author":"Jo","year":"2014","journal-title":"Invest New Drugs"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S271008","article-title":"The Activity and Safety of Anlotinib for Patients With Extremity Desmoid Fibromatosis: A Retrospective Study in a Single Institution","volume":"14","author":"Zheng","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz026","article-title":"Tegavivint and the \u03b2-Catenin\/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma","volume":"111","author":"Nomura","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29564","article-title":"Targeting the Notch Pathway: A Potential Therapeutic Approach for Desmoid Tumors","volume":"121","author":"Shang","year":"2015","journal-title":"Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.1994","article-title":"Clinical Activity of the \u03b3-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis)","volume":"35","author":"Kummar","year":"2017","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0607","article-title":"A Phase I, Dose-Finding Study in Patients With Advanced Solid Malignancies of the Oral \u03b3-Secretase Inhibitor PF-03084014","volume":"21","author":"Messersmith","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0233","article-title":"Pharmacoepidemiology of Clinically Relevant Hypothyroidism and Hypertension From Sunitinib and Sorafenib","volume":"22","author":"Walko","year":"2017","journal-title":"Oncologist"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0281","article-title":"Desmoid Tumors: Clinical Features and Treatment Options for Advanced Disease","volume":"16","author":"Kasper","year":"2011","journal-title":"Oncologist"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0336","article-title":"Cyclooxygenase-2 and Platelet-Derived Growth Factor Receptors as Potential Targets in Treating Aggressive Fibromatosis","volume":"13","author":"Signoroni","year":"2007","journal-title":"Clin Cancer Res an Off J Am Assoc Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.830672\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T04:26:38Z","timestamp":1642047998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.830672\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":31,"alternative-id":["10.3389\/fonc.2021.830672"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.830672","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2022,1,13]]},"article-number":"830672"}}